User: Guest  Login
Document type:
journal article 
Author(s):
Baumann, K; Pfisterer, J; Wimberger, P; Burchardi, N; Kurzeder, C; du Bois, A; Loibl, S; Sehouli, J; Huober, J; Schmalfeldt, B; Vergote, I; Lück, HJ; Wagner, U 
Title:
Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. 
Abstract:
The aim of this study was to select the best catumaxomab regimen for further investigation in ovarian cancer based on confirmed tumour response.Randomised open-label phase IIa study in women with platinum-resistant or -refractory epithelial ovarian cancer. Catumaxomab (6-hour intraperitoneal infusion on days 0, 3, 7 and 10) was administered at a low (10, 10, 10 and 10 ?g) or high dose (10, 20, 50 and 100 ?g). Responders were patients with either a complete (CR) or partial (PR) response.Forty-fiv...    »
 
Journal title abbreviation:
Gynecol Oncol 
Year:
2011 
Journal volume:
123 
Journal issue:
Pages contribution:
27-32 
Language:
eng 
Print-ISSN:
0090-8258 
TUM Institution:
Frauenklinik und Poliklinik